Decreased Expression of ACADSB Predicts Poor Prognosis in Clear Cell Renal Cell Carcinoma

被引:14
|
作者
Liu, Xianhui [1 ]
Zhang, Weiyu [1 ]
Wang, Huanrui [2 ]
Zhu, Lin [1 ]
Xu, Kexin [1 ]
机构
[1] Peking Univ Peoples Hosp, Dept Urol, Beijing, Peoples R China
[2] Peking Univ Peoples Hosp, Peking Univ Appl Lithotripsy Inst, Beijing, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2022年 / 11卷
基金
中国国家自然科学基金;
关键词
renal cancer; ACADSB; prognosis; biomarker; TCGA; DEHYDROGENASE-DEFICIENCY; GENE-EXPRESSION; FERROPTOSIS; METABOLISM; PROMOTES; ISOLEUCINE;
D O I
10.3389/fonc.2021.762629
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundPrevious reports have shown that short/branched chain acyl-CoA dehydrogenase (ACADSB) plays an important role in glioma, but its role in clear cell renal carcinoma (ccRCC) has not been reported. MethodsThe TIMER and UALCAN databases were used for pan-cancer analysis. RNA sequencing and microarray data of patients with ccRCC were downloaded from the Cancer Genome Atlas and Gene Expression Omnibus database. The differential expression of ACADSB in ccRCC and normal kidney tissues was tested. Correlations between ACADSB expression and clinicopathological parameters were assessed using the Wilcoxon test. The influences of ACADSB expression and clinicopathological parameters on overall survival were assessed using Cox proportional hazards models. Gene set enrichment analysis (GSEA) was performed to explore the associated gene sets enriched in different ACADSB expression phenotypes. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed on genes with similar expression patterns to ACADSB. Correlations between ACADSB and ferroptosis-related genes were assessed using Spearman's correlation analysis. ResultsPan-cancer analysis revealed that ACADSB is down-regulated in multiple cancers, and decreased expression of ACADSB correlates with poor prognosis in certain types of cancer. Differential expression analyses revealed that ACADSB was down-regulated in ccRCC, indicating that ACADSB expression could be a single significant parameter to discriminate between normal and tumor tissues. Clinical association analysis indicated that decreased ACADSB expression was associated with high tumor stage and grade. The Cox regression model indicated that low ACADSB expression was an independent risk factor for the overall survival of patients with ccRCC. GSEA showed that 10 gene sets, including fatty acid (FA) metabolism, were differentially enriched in the ACADSB high expression phenotype. GO and KEGG pathway enrichment analysis revealed that ACADSB-related genes were significantly enriched in categories related to FA metabolism, branched-chain amino acid (BCAA) metabolism, and iron regulation. Spearman's correlation analysis suggested that the expression of ACADSB was positively correlated with the expression of ferroptosis driver genes. ConclusionsACADSB showed good diagnostic and prognostic abilities for ccRCC. The downregulation of ACADSB might promote tumorigenesis and tumor progression by inhibiting FA catabolism, BCAA catabolism, and ferroptosis in ccRCC.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Elevated expression of LIF predicts a poor prognosis and promotes cell migration and invasion of clear cell renal cell carcinoma
    Zhong, Wenting
    Liu, Hongxia
    Li, Feng
    Lin, Youyu
    Ye, Yan
    Xu, Luyun
    Li, ShengZhao
    Chen, Hui
    Li, Chengcheng
    Lin, Yuxuan
    Zhuang, Wei
    Lin, Yao
    Wang, Qingshui
    [J]. FRONTIERS IN ONCOLOGY, 2022, 12
  • [22] Low ACADM expression predicts poor prognosis and suppressive tumor microenvironment in clear cell renal cell carcinoma
    Zhou, Libin
    Yin, Min
    Guo, Fei
    Yu, Zefeng
    Weng, Guobin
    Long, Huimin
    [J]. SCIENTIFIC REPORTS, 2024, 14 (01):
  • [23] Hemoglobin β Expression Is Associated with Poor Prognosis in Clear Cell Renal Cell Carcinoma
    Kurota, Yuta
    Takeda, Yuji
    Ichiyanagi, Osamu
    Saitoh, Shinichi
    Ito, Hiromi
    Naito, Sei
    Asao, Hironobu
    Tsuchiya, Norihiko
    [J]. BIOMEDICINES, 2023, 11 (05)
  • [24] Decreased expression of TXNIP is associated with poor prognosis and immune infiltration in kidney renal clear cell carcinoma
    Liu, Wanlu
    Xiao, Zhen
    Dong, Mingyou
    Li, Xiaolei
    Huang, Zhongshi
    [J]. ONCOLOGY LETTERS, 2024, 27 (03)
  • [25] Overexpression of IRF3 Predicts Poor Prognosis in Clear Cell Renal Cell Carcinoma
    Wu, Jun
    Leng, Xuefeng
    Pan, Zhengbo
    Xu, Linfei
    Zhang, Haitao
    [J]. INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2021, 14 : 5675 - 5692
  • [26] Decreased SATB2 expression is associated with metastasis and poor prognosis in human clear cell renal cell carcinoma
    Guo, Changcheng
    Xiong, Dabo
    Yao, Xudong
    Gu, Wenyu
    Zhang, Haimin
    Yang, Bin
    Peng, Bo
    Liu, Min
    Zheng, Junhua
    [J]. INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2015, 8 (04): : 3710 - 3718
  • [27] Decreased expression of HADH is related to poor prognosis and immune infiltration in kidney renal clear cell carcinoma
    Jiang, Huiming
    Chen, Haibin
    Wan, Pei
    Chen, Nanhui
    [J]. GENOMICS, 2021, 113 (06) : 3556 - 3564
  • [28] Decreased expression of dual-specificity phosphatase 9 is associated with poor prognosis in clear cell renal cell carcinoma
    Song Wu
    Yong Wang
    Liang Sun
    Zhiling Zhang
    Zhimao Jiang
    Zike Qin
    Hui Han
    Zhuowei Liu
    Xianxin Li
    Aifa Tang
    Yaoting Gui
    Zhiming Cai
    Fangjian Zhou
    [J]. BMC Cancer, 11
  • [29] Decreased expression of dual-specificity phosphatase 9 is associated with poor prognosis in clear cell renal cell carcinoma
    Wu, Song
    Wang, Yong
    Sun, Liang
    Zhang, Zhiling
    Jiang, Zhimao
    Qin, Zike
    Han, Hui
    Liu, Zhuowei
    Li, Xianxin
    Tang, Aifa
    Gui, Yaoting
    Cai, Zhiming
    Zhou, Fangjian
    [J]. BMC CANCER, 2011, 11
  • [30] High expression levels of DEF6 predicts a poor prognosis for patients with clear cell renal cell carcinoma
    Zhu, Zhen-Peng
    Lin, Lan-Ruo
    Lv, Tong-De
    Xu, Chun-Ru
    Cai, Tian-Yu
    Lin, Jian
    [J]. ONCOLOGY REPORTS, 2020, 44 (05) : 2056 - 2066